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ABSTRACT
Allergen immunotherapy targets Th2 cells activated by specific allergens, which constitutes the basis of allergic
disease. Therefore, this approach has therapeutic potential for a variety of allergic diseases, including asthma,
and may modify their natural course. Immunotherapy results in systemic immunological changes to allergens,
thereby providing clinical benefits in allergic asthma. For example, immunotherapy attenuates T-cell-mediated
airway inflammation by down-modulating Th2 and inducing Th1 differentiation. In addition, immunotherapy in-
duces regulatory T cells, which produce IL-10. Meta-analysis has demonstrated that allergen immunotherapy
improves clinical symptoms and non-specific airway hyperresponsiveness in asthma, and decreases drug re-
quirements. Clinical studies have supported the usefulness if immunotherapy in mild to moderate asthma
cases, particularly in patients with concomitant rhinitis. Several promising novel approaches have emerged as
future immunotherapeutic strategies for the treatment of asthma. Current pharmacotherapy, including inhala-
tional corticosteroids, provides powerful anti-symptomatic benefits in asthma; however, pharmacotherapy can-
not cure or modify the natural course of asthma. As immunotherapy targets the background immunological
state in asthma, it is expected to lead to long-term amelioration or cure. It is hoped that the positioning of aller-
gen immunotherapy as a treatment option will allow the comprehensive management of symptoms in allergic
individuals, and the modification of disease course.
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INTRODUCTION
Allergen immunotherapy constitutes a treatment
method that modifies immunoreactive responses to
specific allergens by administrating allergens that
cause allergic diseases such as asthma. According to
the WHO position paper,1 immunotherapy is effective
for diseases that are associated with type I allergic re-
actions, such as allergic rhinitis and allergic bronchial
asthma. As a result of anti-symptomatic therapies, in-
cluding the use of inhalational corticosteroids (ICS),
management of asthma has markedly improved. Con-
sequently, the use of allergen immunotherapy has
been reduced. However, there is increasing evidence
that ICS does not affect the natural course of
asthma.2-4 Furthermore, ICS does not provide thera-
peutic benefits for symptoms caused by rhinocon-
junctivitis, which is commonly observed in asthmatic
patients. In contrast to ICS, allergen immunotherapy
targets the Th2 cells pathophysiologically activated
by specific allergens, thus providing therapeutic po-
tency for the variety of allergic diseases observed si-
multaneously in allergic individuals, and possibly
modifying the natural course of allergic diseases.1 In
this article, the authors review the current under-
standing of the role of allergen immunotherapy in
asthma and discuss future perspectives of this treat-
ment modality in this field.
MECHANISMS OF ALLERGEN IMMUNO-
THERAPY
Airway inflammation is a key feature of asthma. For
example, infiltration of activated eosinophils is an im-
portant factor and is known to be associated with dis-
ease severity. In successful cases of immunotherapy
in asthma, indexes of airway inflammation, including
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Fig. 1 Eosinophil transendothelial migration induced by 
culture supernatants of peripheral blood mononuclear cels 
(PBMC) obtained from Dermatophagoides farinae (Df)-sen-
sitive atopic asthmatics treated by rush immunotherapy (n = 
5). Df (-); eosinophil migration in response to supernatants of 
PBMC cultured with medium alone. Df (+); eosinophil migra-
tion in response to supernatants of PBMC cultured with Df-
antigen. Data are expressed as mean ± SEM.
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Fig. 2 Efects of rush immunotherapy on production of 
TARC by peripheral blood mononuclear cels obtained from 
house dust mite-sensitive asthmatics. Open bars represent 
data before immunotherapy, and closed bars represent data 
at 16 weeks folowing induction of alergen immunotherapy. 
Data are expressed as mean ± SEM from 8 donors.
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the number of infiltrated eosinophils andor concen-
trations of eosinophil specific-granule proteins, are re-
duced.5-7 For circulating eosinophils to accumulate in
asthmatic airways, they must adhere to and then mi-
grate across vascular endothelial cells. These proc-
esses are largely regulated by cytokineschemokines
produced by various cells, including Th2 cells. Dur-
ing the allergen exposure period in birch pollen
asthma, increased adhesiveness of peripheral blood
eosinophils and increased chemotactic activity for
eosinophils in bronchoalveolar lavage fluid are ob-
served, and these actions are blocked by immuno-
therapy.5,8
The authors previously confirmed that stimulation
of mononuclear leukocytes from house dust mite-
sensitive allergic asthmatics with mite-allergen re-
sults in productions of eosinophil adhesion-inducing
activity, eosinophil chemotactic activity, and eosino-
phil transendothelial migration-inducing activity and
the increases of those parameters were attenuated in
patients treated with allergen immunotherapy (Fig.
1).9-11 These findings suggest that modification of the
responsiveness of T cells, particularly Th2 cells, to
specific allergens by immunotherapy results in the
suppression of eosinophil accumulation in the air-
ways. These effects are likely to involve down-
regulation of Th2 cells.
It has been demonstrated that the production of
Th2 cytokines, such as IL-4 and IL-5, is decreased by
immunotherapy.8,12 We recently found that immuno-
therapy attenuates the house dust mite allergen-
specific production of TARC, a potent chemokine acti-
vator of Th2 cells, from peripheral blood mononu-
clear cells obtained from patients with house dust
mite-sensitive allergic asthma, thus suggesting that
immunotherapy can reduce accumulation of Th2 cells
during allergen exposure (Fig. 2). Therefore, immu-
notherapy results in systemic immunological changes
in response to allergens, and provides some clinical
benefits in allergic asthma. In addition to modulating
effects on the Th2 cascade, immunotherapy induced
differentiation to the Th1, rather than the Th2, pheno-
type in Th0 cells.13
It has been reported13 that allergen-challenge-
induced expression of IL-12 mRNA in the skin was
augmented by immunotherapy. These findings sup-
port the notion that immunotherapy attenuates T-cell-
mediated airway inflammation via down-modulation
of Th2 and induction of Th1 differentiation. There is
also increasing evidence that immunotherapy in-
duces regulatory T cells (Treg), which produce IL-10
and down-modulate allergic inflammation.14-16 For ex-
ample, in bee venom allergy, immunotherapy in-
creases the production of IL-10, which is associated
with inhibitory effects in response to specific aller-
gens. However, recent investigations using immuno-
therapy with Th1 adjuvants, such as CpG-motif, have
shown some clinical benefits without production of
IL-10, thus indicating the need for further research to
elucidate the significance of TregIL-10. Involvement
of TregIL-10 in immunotherapy for Th2 suppression
may be regulated by multiple factors, including aller-
gen, adjuvant and time of assessment.
CURRENT STATUS OF ALLERGEN IMMU-
NOTHERAPY IN ASTHMA
The clinical indications for immunotherapy in asthma
are not fully established; however, this therapy
should be considered for allergic asthma patients
who have identified environmental aero allergens that
Immunotherapy in Asthma
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Table Clinical efects in terms of step-down rate after rush 
immunotherapy in house dust mite-sensitive asthmatics
Duration FEV1%
<10 y>= 10 y<70%>= 70%
5 (29.4%)18 (54.5%)8 (66.7%)15 (39.5%)Unchanged:
12 (70.6%)15 (45.5%)4 (33.3%)23 (60.5%)Improved:
P = 0.043P = 0.009
are difficult to avoid or for cases that are not severe
and present normal pulmonary function. This ap-
proach was outlined in the recent US asthma guide-
line Expert Panel 3.17 In asthma, meta-analysis has
demonstrated that allergen immunotherapy improves
clinical symptoms and non-specific airway hyperre-
sponsiveness, and decreases drug requirements.18
For immunotherapy to be successful, the mainte-
nance allergen dose to be administered should be
sufficiently high. In rush immunotherapy, patients
are hospitalized and repeatedly injected under clini-
cally controlled conditions, and the target concentra-
tion is easily achieved in several days, with clinical ef-
fects being seen rapidly19; improvement in symptom
medication scores and allergen-specific bronchial hy-
perresponsiveness typically appears within several
weeks. Using this method, we observed that clinical
effects, based on the rate of obtaining step-down of
asthma severity, is significantly less in patients with
more than 10 years of disease or FEV1% of less than
70% (Table). Therefore, it is conceivable that immu-
notherapy would be beneficial for asthmatics with
early-stage allergic asthma, without development of
airway remodeling.
What happens if immunotherapy is prescribed in
addition to ICS? Current pharmacotherapy, including
ICS, recommended by the latest guidelines tends to
rapidly improve symptoms in mild to moderate
asthma. Maestrelli et al.20 investigated the additional
effects of immunotherapy when it was combined with
pharmacotherapy according to the Global Initiative
for Asthma (GINA) guidelines in mild to moderate
disease in mite-sensitive asthmatic patients. The im-
munotherapy group showed partial suppression in
mite-induced immediate skin reactions, decreased
frequency of rescue use of short-acting β2-agonist,
and improved peak expiratory flow rate, thus suggest-
ing immunotherapy provides additive effects in pa-
tients treated with ICS. More recently, Garcia-
Robaina et al.21 investigated the effects of a depig-
mented polymerized allergen vaccine containing a
50% mixture of Dermatophagoides pteronyssinus and
Dermatophagoides farina on mild to moderate
asthma, and found that the median improvement in
total symptom and medication scores in the active
versus placebo group was 53.8% and 58.1%, respec-
tively. This study also demonstrated that this immu-
notherapy improves symptoms of rhinoconjunctivitis,
thereby confirming that immunotherapy acts as an
active systemic therapy for allergic individuals. In this
context, Marogna et al.22 compared the effects of sub-
lingual immunotherapy (SLIT) and ICS in patients
with mild asthma and concomitant rhinitis due to
grass pollen allergy. After a run-in season, patients
were randomized to either 800 μgday budesonide,
an ICS, during the pollen season or continuous grass
SLIT for 5 years. Asthma symptoms decreased sig-
nificantly in both groups; however, improvements
were greater in the SLIT patients at 3 and 5 years.
Furthermore, a decrease in both nasal symptoms and
nasal eosinophils was observed only in the SLIT
group. These results indicate that SLIT is equally ef-
fective as ICS in treating seasonal asthma and pro-
vides benefits in treating rhinitis symptoms.
Taken together, these clinical studies confirmed
the rationale of current US guideline EPR3, and sup-
port the usefulness of immunotherapy in mild to mod-
erate asthma, particularly in those with rhinoconjunc-
tivitis.
MODIFICATION OF NATURAL HISTORY BY
IMMUNOTHERAPY
What about the significance of immunotherapy in its
original role of modification of the natural history of
allergic diseases such as asthma? The approaches de-
scribed in the following section provide promising
data. As noted above, it is speculated that immuno-
therapy would be less effective in asthmatic patients
with longer disease period because of development of
airway remodeling. Moller et al.23 investigated the ef-
fects of immunotherapy on onset of asthma in pollen
allergy rhinitis patients. Non-specific airway hyperre-
sponsiveness during the pollen season improved only
in the active treatment group. After three years of fol-
low up, the ratio of asthma development was signifi-
cantly lower in the immunotherapy treatment group
(21%) than in the control group (44%). These results
suggest that immunotherapy is more effective when
introduced at early stages.
Thus, Di Rienzo et al.24 investigated whether mite-
allergen immunotherapy using SLIT can improve the
natural course of children suffering from mite allergy.
At the end of a 4- to 5-year course of SLIT treatment
and a further 4 to 5 years after SLIT discontinuation,
there was a significant reduction in the presence of
asthma in the treated patients, as compared with
baseline. On the other hand, in the control group, no
clinical changes were observed after 5 and 10 years of
follow-up. There was a highly significant difference
between the two groups, at both the end of SLIT and
after 5 years. This study demonstrates that SLIT im-
proves the prognosis of children with mite allergy,
and that clinical efficacy is maintained for 4 to 5 years
after discontinuation.
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NEW APPROACHES FOR ALLERGEN IM-
MUNOTHERAPY
The following novel approaches constitute promising
future immunotherapy modalities for asthma. It has
been demonstrated that Th1 adjuvants, such as
liposome, monophosphoryl lipid A (MPL) or the im-
munostimulatory DNA sequence CpG motif, may fa-
cilitate the action of allergen immunotherapy. For ex-
ample, Basomba et al.25 conducted a double blinded
comparative study of immunotherapy using liposomal
mite allergen on mild to moderate asthma. Approxi-
mately half (46%) of the immunotherapy group
showed a decrease in symptom-medication scores of
more than 60%, while fewer patients (only 12%) in the
placebo group showed such improvement. In the ac-
tive treatment group, mite-specific IgG4 was in-
creased, while allergen-specific bronchial responsive-
ness was improved. It was meaningful to demonstrate
that liposome, which is known to be a Th1 adjuvant,
can be used for allergen immunotherapy in asthma;
however, it is unclear whether this modification can
overcome current treads in conventional immuno-
therapy.
Drachenberg et al.26 examined whether a grass
pollen-specific vaccine containing MPL, a potent Th1
adjuvant and a ligand for toll-like receptor 4, would
modify allergic symptoms in grass pollen-sensitive
subjects. Tyrosine-absorbed glutaraldehyde-modified
grass pollen extract containing MPL adjuvant was
used. After only four preseasonal injections, the vac-
cine containing MPL reduced nasal symptoms, ocular
symptoms, and combined symptom and medication
scores.
Tulik et al.27 investigated whether a conjugate of
the major ragweed allergen Amb a 1 and CpG motif
(A1C) would modify asthma and rhinitis due to rag-
weed hay fever. No severe side effects were ob-
served, and the active treatment was well tolerated.
In the active group, nasally administered allergen in-
duced IL-4 producing cells were blocked while IFN-γ
was increased, confirming an immunological shift
from the Th2 to Th1 system. During the pollen sea-
son, the AIC group showed significantly fewer
asthma and rhinitis symptoms as compared with the
control group. Creticos et al.28 also reported that a 6-
week regimen of the AIC vaccine appeared to offer
long-term clinical efficacy in the treatment of ragweed
allergic rhinitis: During the first ragweed season, the
AIC group had better peak-season rhinitis scores
than the placebo group and a clinical benefits were
again observed in the subsequent ragweed season.
These studies are important for demonstrating that
induction of Th1 and reduction of Th2 response act
as mechanisms of immunotherapy, thus raising the
future possibility of additional Th1 adjuvants.
There is increasing evidence that recombinant
DNA technology has the potential to produce
allergen-specific immunotherapy vaccines.29,30 Pauli
et al.29 evaluated the effectiveness of a recombinant
birch pollen allergen vaccine in patients with birch
pollen allergy. A randomized, double-blind, placebo-
controlled trial was undertaken in order to compare
the following three vaccines in 134 adults with birch
pollen allergy: recombinant birch pollen allergen vac-
cine (rBet v 1a), licensed birch pollen extract, natural
purified birch pollen allergen (nBet v 1), and placebo.
Significant reductions (about 50%) in rhinoconjunc-
tivitis symptoms, rescue medication, and skin sensi-
tivities were observed in the three actively treated
groups, as compared with the placebo. No severe sys-
temic adverse events were observed in the rBet v 1-
treated group. These results indicate that the rBet v
1-based vaccine is safe and effective in treating birch
pollen allergy.
FUTURE PERSPECTIVES
Application of immunotherapy upon onset of asthma
is clinically feasible in Japan with the aim of preven-
tion. Patients with Japanese cedar pollinosis, for ex-
ample, may be candidates for immunotherapy in
terms of preventing development of asthma. The pre-
sent study also suggests the usefulness of early inter-
vention in producing improvements. The study on
mite allergy using SLIT strongly suggests that immu-
notherapy can improve the natural course of allergic
diseases, including asthma, in children. However, it
remains to be elucidated whether such effects can
also be achieved in adult asthmatics.
Among recent progress and newly developed ap-
proaches regarding allergen immunotherapy, liposo-
mal allergen vaccination is promising; however, it
should be clarified whether this method is better
than conventional allergen immunotherapy. On the
other hand, selective Th1 adjuvants, such as CpG mo-
tif or MPL, have the potential to become useful thera-
pies for allergic asthma, such as in mite allergy. In
any case, the application of Th1 system adjuvant may
be useful as a modified vaccine approach in immuno-
therapy. Immunotherapy using recombinant allergen
would provide a further possibility to improve this
form of therapy. The results of a study by Pauli et
al.29 are extremely promising, and suggest the possi-
ble use of this approach in dust mite allergy.
Current pharmacotherapy, such as ICS, provides
powerful anti-symptomatic benefits in asthma; how-
ever, it does not cure or modify the natural disease
course. As immunotherapy targets the immunologi-
cal background in asthma, including pathological acti-
vation of Th2 cells, it is expected to lead to long-term
amelioration of asthma. It is hoped that the novel ap-
proaches described in this article will become more
sophisticated and provide better efficacy, and that the
positioning of allergen immunotherapy as a treatment
option for comprehensive management of allergy
symptoms and for modification of disease course.
Immunotherapy in Asthma
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